TRPX Therapix Biosciences Ltd.

1.49
-0.01  -1%
Previous Close 1.5
Open 1.45
Price To Book -8.77
Market Cap 6,574,014
Shares 4,412,090
Volume 62,045
Short Ratio
Av. Daily Volume 87,272
Stock charts supplied by TradingView

NewsSee all news

  1. Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

    TEL AVIV, Israel, Nov. 20, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  2. SOL Global Portfolio Company Heavenly Rx, Ltd. Enters Into MOU for Business Combination with Therapix Biosciences

     Parties to Move Towards Definitive Agreements to Merge Heavenly Rx With Cutting Edge Cannabinoid Pharmaceutical Company Heavenly Rx Nominates former Kimberly Clark Chief Marketing Officer and Kellogg's former Chief

  3. Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

    TEL AVIV, Israel, Nov. 18, 2019 Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), announced today that it entered into a memorandum of understanding ("MOU") with Heavenly Rx,

  4. Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, Nov. 13, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  5. Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

    TEL AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a trial likely to be completed 2H 2020 (Germany).
THX-110
Tourette Syndrome
Phase 2a trial ongoing.
THX-110
Chronic pain
Phase 2a top-line data due 2H 2019.
THX-110
Obstructive Sleep Apnea (OSA)

Latest News

  1. Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

    TEL AVIV, Israel, Nov. 20, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  2. SOL Global Portfolio Company Heavenly Rx, Ltd. Enters Into MOU for Business Combination with Therapix Biosciences

     Parties to Move Towards Definitive Agreements to Merge Heavenly Rx With Cutting Edge Cannabinoid Pharmaceutical Company Heavenly Rx Nominates former Kimberly Clark Chief Marketing Officer and Kellogg's former Chief

  3. Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

    TEL AVIV, Israel, Nov. 18, 2019 Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), announced today that it entered into a memorandum of understanding ("MOU") with Heavenly Rx,

  4. Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, Nov. 13, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  5. Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

    TEL AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  6. Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

    TEL AVIV, Israel, Oct. 15, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today

  7. Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

    TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  8. Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

    TEL AVIV, Israel, Aug. 27, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of